Differential estrogen receptor subtype modulators: Assessment of estrogen receptor subtype-binding selectivity and transcription-regulating properties of new cycloalkyl pyrazoles

Journal of Steroid Biochemistry and Molecular Biology

Volumn 117, Issue 4-5, 2009, Pages 159-167

  Alexi, Xanthippi ^a   Kasiotis, Konstantinos M ^b   Fokialakis, Nikolaos ^c   Lambrinidis, George ^c   Meligova, Aggeliki K ^a   Mikros, Emmanuel ^c   Haroutounian, Serkos A ^b   Alexis, Michael N ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cycloalkyl fused pyrazoles; Estrogen receptor modulators; LNCaP; MCF 7

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; ANTIESTROGEN; CYCLOALKANE DERIVATIVE; CYCLOHEXANE; CYCLOPENTANE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PYRAZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL GROWTH; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME SPECIFICITY; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HORMONE DETERMINATION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; BINDING SITES; CELL LINE, TUMOR; ESTRADIOL; HUMANS; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; PYRAZOLES; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSCRIPTION, GENETIC;

EID: 70350547755     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.006     Document Type: Article

References (40)

1. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., and Gustafsson J.-A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87 3 (2007) 905-931
2. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C., Katzenellenbogen J.A., Korach K.S., Maggi A., Muramatsu M., Parker M.G., and Gustafsson J.-A. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58 4 (2006) 773-781
3. Levin E.R., and Pietras R.J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res. Treat. 108 3 (2008) 351-361
4. Lambrinidis G., Halabalaki M., Katsanou E., Skaltsounis A.-L., Alexis M., and Mikros E. The estrogen receptor and polyphenols: molecular simulation studies of their interactions, a review. Environ. Chem. Lett. 4 3 (2006) 159-174
5. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., and Katzenellenbogen J.A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 43 26 (2000) 4934-4947
6. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., Katzenellenbogen J.A., Agard D.A., and Greene G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Mol. Biol. 9 5 (2002) 359-364
7. Skretas G., Meligova A.K., Villalonga-Barber C., Mitsiou D.J., Alexis M.N., Micha-Screttas M., Steele B.R., Screttas C.G., and Wood D.W. Engineered chimeric enzymes as tools for drug discovery: generating reliable bacterial screens for the detection, discovery, and assessment of estrogen receptor modulators. J. Am. Chem. Soc. 129 27 (2007) 8443-8457
8. Fokialakis N., Lambrinidis G., Mitsiou D.J., Aligiannis N., Mitakou S., Skaltsounis A.-L., Pratsinis H., Mikros E., and Alexis M.N. A new class of phytoestrogens: evaluation of the estrogenic activity of deoxybenzoins. Chem. Biol. 11 3 (2004) 397-406
9. Chang E.C., Charn T.H., Park S.-H., Helferich W.G., Komm B., Katzenellenbogen J.A., and Katzenellenbogen B.S. Estrogen receptors {alpha} and {beta} as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 22 5 (2008) 1032-1043
10. Weihua Z., Saji S., Makinen S., Cheng G., Jensen E.V., Warner M., and Gustafsson J.A. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. U.S.A. 97 11 (2000) 5936-5941
11. Frasor J., Barnett D.H., Danes J.M., Hess R., Parlow A.F., and Katzenellenbogen B.S. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 144 7 (2003) 3159-3166
12. Johnson S.M., Maleki-Dizaji M., Styles J.A., and White I.N. Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen. Endocr. Relat. Cancer 14 2 (2007) 337-350
13. Kasiotis K.M., Mendorou C., Haroutounian S.A., and Alexis M.N. High affinity 17alpha-substituted estradiol derivatives: synthesis and evaluation of estrogen receptor agonist activity. Steroids 71 3 (2006) 249-255
14. Hoekstra W.J., Patel H.S., Liang X., Blanc J.B., Heyer D.O., Willson T.M., Iannone M.A., Kadwell S.H., Miller L.A., Pearce K.H., Simmons C.A., and Shearin J. Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling. J. Med. Chem. 48 6 (2005) 2243-2247
15. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., Warner M., and Gustafsson J.A. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. U.S.A. 99 24 (2002) 15578-15583
16. Mueller S.O., Clark J.A., Myers P.H., and Korach K.S. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. Endocrinology 143 6 (2002) 2357-2365
17. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61 6 (2001) 2537-2541
18. Lazennec G., Alcorn J.L., and Katzenellenbogen B.S. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol. Endocrinol. 13 6 (1999) 969-980
19. Chang E.C., Frasor J., Komm B., and Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147 10 (2006) 4831-4842
20. Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., and Ho S.M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159 1 (2001) 79-92
21. Imamov O., Morani A., Shim G.J., Omoto Y., Thulin-Andersson C., Warner M., and Gustafsson J.A. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. U.S.A. 101 25 (2004) 9375-9380
22. Guerini V., Sau D., Scaccianoce E., Rusmini P., Ciana P., Maggi A., Martini P.G., Katzenellenbogen B.S., Martini L., Motta M., and Poletti A. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res. 65 12 (2005) 5445-5453
23. Maggiolini M., Recchia A.G., Carpino A., Vivacqua A., Fasanella G., Rago V., Pezzi V., Briand P.A., Picard D., and Ando S. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J. Mol. Endocrinol. 32 3 (2004) 777-791
24. Takahashi Y., Perkins S.N., Hursting S.D., and Wang T.T.Y. 17beta-estradiol differentially regulates androgen-responsive genes through estrogen receptor-beta- and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol. Carcinog. 46 2 (2007) 117-129
25. Nishiguchi G.A., Rodriguez A.L., and Katzenellenbogen J.A. Diaryl-dialkyl-substituted pyrazoles: regioselective synthesis and binding affinity for the estrogen receptor. Bioorg. Med. Chem. Lett. 12 6 (2002) 947-950
26. Kasiotis K.M., Fokialakis N., and Haroutounian S.A. Synthesis of novel conformationally constrained pyrazolo[4,3-c]quinoline derivatives as potential ligands for the estrogen receptor. Synthesis 2006 11 (2006) 1791-1802
27. Liu H.-J., Ly T.W., Tai C.-L., Wu J.-D., Liang J.-K., Guo J.-C., Tseng N.-W., and Shia K.-S. A modified Robinson annulation process to [alpha],[alpha]-disubstituted-[beta],[gamma]-unsaturated cyclohexanone system. Application to the total synthesis of nanaimoal. Tetrahedron 59 8 (2003) 1209-1226
28. Norman B.H., Dodge J.A., Richardson T.I., Borromeo P.S., Lugar C.W., Jones S.A., Chen K., Wang Y., Durst G.L., Barr R.J., Montrose-Rafizadeh C., Osborne H.E., Amos R.M., Guo S., Boodhoo A., and Krishnan V. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J. Med. Chem. 49 21 (2006) 6155-6157
29. Halabalaki M., Alexi X., Aligiannis N., Lambrinidis G., Pratsinis H., Florentin I., Mitakou S., Mikros E., Skaltsounis A.-L., and Alexis M.N. Estrogenic activity of isoflavonoids from Onobrychis ebenoides. Planta Med. 72 06 (2006) 488-493
30. Gritzapis A.D., Baxevanis C.N., Missitzis I., Katsanou E.S., Alexis M.N., Yotis J., and Papamichail M. Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay. Breast Cancer Res. Treat. 80 1 (2003) 1-13
31. Katsanou E.S., Halabalaki M., Aligiannis N., Mitakou S., Skaltsounis A.L., Alexi X., Pratsinis H., and Alexis M.N. Cytotoxic effects of 2-arylbenzofuran phytoestrogens on human cancer cells: modulation by adrenal and gonadal steroids. J. Steroid Biochem. Mol. Biol. 104 3-5 (2007) 228-236
32. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 6652 (1997) 753-758
33. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., Ljunggren J., Gustafsson J.A., and Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 17 (1999) 4608-4618
34. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., and Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 140 2 (1999) 800-804
35. Meyers M.J., Sun J., Carlson K.E., Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J. Med. Chem. 42 13 (1999) 2456-2468
36. Harrington W.R., Sheng S., Barnett D.H., Petz L.N., Katzenellenbogen J.A., and Katzenellenbogen B.S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell Endocrinol. 206 1-2 (2003) 13-22
37. Manas E.S., Xu Z.B., Unwalla R.J., and Somers W.S. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure 12 12 (2004) 2197-2207
38. Gangloff M., Ruff M., Eiler S., Duclaud S., Wurtz J.M., and Moras D. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J. Biol. Chem. 276 18 (2001) 15059-15065
39. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 5564 (2002) 2465-2468
40. He D., and Falany C.N. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells. Prostate 67 12 (2007) 1318-1329